The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
Its a major breakthrough for women’s ovarian cancer care in Europe
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
This marks a meaningful step in the company's continued expansion in the region
Subscribe To Our Newsletter & Stay Updated
